4.7 Article

Serum circulating proteins from pediatric patients with dilated cardiomyopathy cause pathologic remodeling and cardiomyocyte stiffness

期刊

JCI INSIGHT
卷 6, 期 19, 页码 -

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/jci.insight.148637

关键词

-

资金

  1. NIH [K24 HL150630, R01 HL107715, R01 HL126928, K25HL148386, R01 HL147064]
  2. Trans-Atlantic Network of Excellence grant from the Leducq Foundation [14 CVD 03]
  3. John Patrick Albright
  4. Jack Cooper Millisor Chair in Pediatric Heart Disease
  5. Rose Community Foundation
  6. Colorado CTSA Grant [UL1 TR002535]
  7. Italian Ministry of Education, Universities and Research [20173ZW ACS]

向作者/读者索取更多资源

The study found that in serum from DCM patients, MDK protein is upregulated and treatment of NRVMs can activate FGP. Circulating proteins promote pathological changes in gene expression and cellular stiffness, while circulating miRNAs have a protective effect against these changes.
Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy and main indication for heart transplantation in children. Therapies specific to pediatric DCM remain limited due to lack of a disease model. Our previous study showed that treatment of neonatal rat ventricular myocytes (NRVMs) with serum from nonfailing or DCM pediatric patients activates the fetal gene program (FGP). Here we show that serum treatment with proteinase K prevents activation of the FGP, whereas RNase treatment exacerbates it, suggesting that circulating proteins, but not circulating miRNAs, promote these pathological changes. Evaluation of the protein secretome showed that midkine (MDK) is upregulated in DCM serum, and NRVM treatment with MDK activates the FGP. Changes in gene expression in serum-treated NRVMs, evaluated by next generation RNA-Seq, indicated extracellular matrix remodeling and focal adhesion pathways were upregulated in pediatric DCM serum and in DCM serum-treated NRVMs, suggesting alterations in cellular stiffness. Cellular stiffness was evaluated by Atomic Force Microscopy, which showed an increase in stiffness in DCM serum-treated NRVMs. Of the proteins increased in DCM sera, secreted frizzled-related protein 1 (sFRP1) was a potential candidate for the increase in cellular stiffness, and sFRP1 treatment of NRVMs recapitulated the increase in cellular stiffness observed in response to DCM serum treatment. Our results show that serum circulating proteins promoted pathological changes in gene expression and cellular stiffness, and circulating miRNAs were protective against pathological changes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据